Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2020 Oct 1;21(10):2827-2836.
doi: 10.31557/APJCP.2020.21.10.2827.

Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis

Ikhwan Rinaldi  1 , Melva Louisa  2 , Fikri Ichsan Wiguna  3 , Elizabeth Budiani  3 , Jeffrey Christian Mahardhika  3 , Khairul Hukmi  3
Affiliations
Meta-Analysis

Prognostic Significance of Fms-Like Tyrosine Kinase 3 Internal Tandem Duplication Mutation in Non-Transplant Adult Patients with Acute Myeloblastic Leukemia: A Systematic Review and Meta-Analysis

Ikhwan Rinaldi et al. Asian Pac J Cancer Prev. .

Abstract

Background: Fms-like tyrosine kinase-3, internal tandem duplication (FLT3-ITD) mutation, is a known predictor for worse outcome in patients with acute myeloblastic leukemia (AML). However, the prognostic significance of FLT3-ITD mutation in adult, non-transplant patients is still unclear therefore we conducted a systematic review and meta-analysis to explain this issue. The main outcome was overall survival (OS), while additional outcomes included event-free survival (EFS).

Methods: Seven Databases (ScienceDirect, Scopus, PubMed, Cochrane, SpringerLink, ProQuest, and EBSCOhost) were searched up to August 2020. Studies investigating the prognostic value of AML in adults with FLT3-ITD mutational status were selected. Studies which patients had received transplantation, diagnosed with acute promyelocytic leukemia (APL) or secondary AML were excluded. The selected studies were divided into subgroups based on their cytogenetic profile. Summary hazard ratios (HR) and 95% confidence intervals (CI) were calculated using fixed-effects models. Heterogeneity tests were conducted and presented in I2 value. Forest plot was presented to facilitate understanding of the results. Publication bias was analyzed by Funnel Plot test.

Results: A total of ten studies describing research conducted from 1999 to 2020, met the inclusion criteria for this study. Nine studies reported OS and four studies reported EFS in HR. The highest HR for OS is 6.33 (95% CI, 2.61-15.33; p < 0.001), for EFS is 3.58 (95% CI, 1.59 - 8.05); p = 0.002)., while the lowest for OS is 1.33 (95% CI, 0.88-2.01; P = 0.174) and for EFS is 1.29 (95% CI, 0.75-2.23; p = 0.34). Nine studies were included in meta-analysis with HR for OS 1.91 (95% CI, 1.59-2.30, p < 0.00001), whereas 4 studies were included in meta-analysis for EFS with HR 1.64 (95% CI, 1.25-2.14; p = 0.0003).

Conclusion: FLT3-ITD mutation is associated with worse prognosis in adult, non-transplant patients with AML, both for OS and EFS.

Keywords: Acute; Fms-Like Tyrosine Kinase 3; Leukemia; myeloid; prognostic significance.

PubMed Disclaimer

Figures

Figure 1
Figure 1
PRISMA Flow Chart for Searching Strategy
Figure 2
Figure 2
Summary of Risk of Bias Analysis among Studies
Figure 3
Figure 3
Intra-Study Analysis of Risk of Bias
Figure 4
Figure 4
Forest Plot of the Association between FLT3-ITD Mutation and Overall Survival (OS) among Adult Acute Myeloblastic Leukemia Ppatients
Figure 5
Figure 5
Forest Plot of the Association between FLT3-ITD Mutation and Event-Free Survival (EFS) among Adult, Acute Myeloblastic Leukemia Patient
Figure 6
Figure 6
Funnel Plot of the Association between FLT3-ITD Mutation and Overall Survival (OS) among Adult Acute Myeloblastic Leukemia Patients
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Almeida AM, Ramos F. Acute myeloid leukemia in the older adults. Leuk Res Rep. 2016;6:1–7. - PMC - PubMed
    1. Ardestani MT, Kazemi A, Chahardouli B, et al. FLT3-ITD compared with DNMT3A R882 mutation is a more powerful independent inferior prognostic factor in adult acute myeloid leukemia patients after allogeneic hematopoietic stem cell transplantation: A retrospective cohort study. Turkish J Hematol. 2018;35:158–67. - PMC - PubMed
    1. Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. Blood Adv. 2017;1:1312–23. - PMC - PubMed
    1. Coombs CC, Tavakkoli M, Tallman MS. Acute promyelocytic Leukemia: Where did we start, where are we now, and the future. Blood Cancer J. 2015;5:e304–9. - PMC - PubMed
    1. Dang H, Chen Y, Kamel-Reid S, Brandwein J, Chang H. CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Hum Pathol. 2013;44:2038–46. - PubMed

Substances